{"id":18546,"date":"2026-03-16T18:07:23","date_gmt":"2026-03-16T12:37:23","guid":{"rendered":"https:\/\/dev.sunpharma.com\/?p=18546"},"modified":"2026-03-16T18:07:45","modified_gmt":"2026-03-16T12:37:45","slug":"sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o","status":"publish","type":"post","link":"https:\/\/dev.sunpharma.com\/he\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/","title":{"rendered":"Sun Pharma Announces US FDA Acceptance of Supplemental  Biologics License (sBLA) Application for ILUMYA\u00ae  (tildrakizumab-asmn) for the Treatment of Adults with Active  Psoriatic Arthritis"},"content":{"rendered":"<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/03\/Sun-Pharma-Announces-US-FDA-Acceptance-of-sBLA-Application-for-ILUMYA.pdf\" class=\"read-more-btn\" target=\"_blank\">Read More<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Read More<\/p>","protected":false},"author":4,"featured_media":17035,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-18546","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressreleases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis - Sun Pharmaceutical Industries Ltd.<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis - Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"og:description\" content=\"Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.sunpharma.com\/he\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T12:37:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-16T12:37:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/Homepage_Innovation-768x514-1-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"514\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ananthi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ananthi\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/\"},\"author\":{\"name\":\"ananthi\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#\\\/schema\\\/person\\\/c7269b4a3d6a22d46bfb1554af8093fa\"},\"headline\":\"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis\",\"datePublished\":\"2026-03-16T12:37:23+00:00\",\"dateModified\":\"2026-03-16T12:37:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/\"},\"wordCount\":26,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Homepage_Innovation-768x514-1-1.jpg\",\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/\",\"name\":\"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis - Sun Pharmaceutical Industries Ltd.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Homepage_Innovation-768x514-1-1.jpg\",\"datePublished\":\"2026-03-16T12:37:23+00:00\",\"dateModified\":\"2026-03-16T12:37:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#\\\/schema\\\/person\\\/c7269b4a3d6a22d46bfb1554af8093fa\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"he-IL\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#primaryimage\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Homepage_Innovation-768x514-1-1.jpg\",\"contentUrl\":\"https:\\\/\\\/dev.sunpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Homepage_Innovation-768x514-1-1.jpg\",\"width\":768,\"height\":514,\"caption\":\"Innovation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/blog\\\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dev.sunpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/\",\"name\":\"Sun Pharmaceutical Industries Ltd.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.sunpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#\\\/schema\\\/person\\\/c7269b4a3d6a22d46bfb1554af8093fa\",\"name\":\"ananthi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"he-IL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g\",\"caption\":\"ananthi\"},\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/he\\\/blog\\\/author\\\/ananthi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis - Sun Pharmaceutical Industries Ltd.","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"he_IL","og_type":"article","og_title":"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis - Sun Pharmaceutical Industries Ltd.","og_description":"Read More","og_url":"https:\/\/dev.sunpharma.com\/he\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_published_time":"2026-03-16T12:37:23+00:00","article_modified_time":"2026-03-16T12:37:45+00:00","og_image":[{"width":768,"height":514,"url":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/Homepage_Innovation-768x514-1-1.jpg","type":"image\/jpeg"}],"author":"ananthi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ananthi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#article","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/"},"author":{"name":"ananthi","@id":"https:\/\/dev.sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"headline":"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis","datePublished":"2026-03-16T12:37:23+00:00","dateModified":"2026-03-16T12:37:45+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/"},"wordCount":26,"commentCount":0,"image":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/Homepage_Innovation-768x514-1-1.jpg","articleSection":["Press Releases"],"inLanguage":"he-IL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/","url":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/","name":"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis - Sun Pharmaceutical Industries Ltd.","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#primaryimage"},"image":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/Homepage_Innovation-768x514-1-1.jpg","datePublished":"2026-03-16T12:37:23+00:00","dateModified":"2026-03-16T12:37:45+00:00","author":{"@id":"https:\/\/dev.sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"breadcrumb":{"@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/"]}]},{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#primaryimage","url":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/Homepage_Innovation-768x514-1-1.jpg","contentUrl":"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/Homepage_Innovation-768x514-1-1.jpg","width":768,"height":514,"caption":"Innovation"},{"@type":"BreadcrumbList","@id":"https:\/\/dev.sunpharma.com\/blog\/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-o\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dev.sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis"}]},{"@type":"WebSite","@id":"https:\/\/dev.sunpharma.com\/#website","url":"https:\/\/dev.sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"},{"@type":"Person","@id":"https:\/\/dev.sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa","name":"ananthi","image":{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"ananthi"},"url":"https:\/\/dev.sunpharma.com\/he\/blog\/author\/ananthi\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/18546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=18546"}],"version-history":[{"count":2,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/18546\/revisions"}],"predecessor-version":[{"id":18548,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/18546\/revisions\/18548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media\/17035"}],"wp:attachment":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=18546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/categories?post=18546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/tags?post=18546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}